Skip to Main Content

Author Details

William Clark
Cancer Research UK Beatson Institute
1993
47
25
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36702176Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration.J Hepatol2023
37580540Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target.Nat Metab2023
36720858Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.Nat Commun2023
34628485p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl<sub>4</sub>.Cell Death Differ2022
35477863CXCR2 inhibition enables NASH-HCC immunotherapy.Gut2022
36477656Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features.Nat Commun2022
33414552The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer.Nat Genet2021
33627783E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.Oncogene2021
34435198Specificity and off-target effects of AAV8-TBG viral vectors for the manipulation of hepatocellular gene expression in mice.Biol Open2021
34079124NOTUM from Apc-mutant cells biases clonal competition to initiate cancer.Nature2021
33985973SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer.Cancer Res2021
34314753MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours.Cancer Lett2021
33431824BRD4-mediated repression of p53 is a target for combination therapy in AML.Nat Commun2021
33397922A RAC-GEF network critical for early intestinal tumourigenesis.Nat Commun2021
32156779RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome.Cancer Res2020
32001510Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence.Genes Dev2020
33033111In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.Life Sci Alliance2020
32200350Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma.Cancer Discov2020
30760720Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.Nat Commun2019
31526760Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.Cancer Cell2019
30914643Author Correction: Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.Nat Commun2019
31032816Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma.Cancers (Basel)2019
29719257CSF1R<sup>+</sup> Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.Cell Rep2018
29925636The ERBB network facilitates KRAS-driven lung tumorigenesis.Sci Transl Med2018
30111642TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence.Sci Transl Med2018
28525743Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.Mol Cell2017
28351383Diverse interventions that extend mouse lifespan suppress shared age-associated epigenetic changes at critical gene regulatory regions.Genome Biol2017
28238662Coordination by Cdc42 of Actin, Contractility, and Adhesion for Melanoblast Movement in Mouse Skin.Curr Biol2017
29135975Transcriptomic profiling of human breast and melanoma cells selected by migration through narrow constraints.Sci Data2017
27457071Mapping H4K20me3 onto the chromatin landscape of senescent cells indicates a function in control of cell senescence and tumor suppression through preservation of genetic and epigenetic stability.Genome Biol2016
27824338ROCK signalling induced gene expression changes in mouse pancreatic ductal adenocarcinoma cells.Sci Data2016
26299965Mitotic Stress Is an Integral Part of the Oncogene-Induced Senescence Program that Promotes Multinucleation and Cell Cycle Arrest.Cell Rep2015
25315154DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.Genome Biol2014
25512559HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia.Genes Dev2014
19595761The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch.Cell Signal2009
15456874c-Jun-deficient cells undergo premature senescence as a result of spontaneous DNA damage accumulation.Mol Cell Biol2004
12717415v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p21 CIP1.Oncogene2003
12932827Estrogen receptor activation function 2 (AF-2) is essential for hormone-dependent transactivation and cell transformation induced by a v-Jun DNA binding domain-estrogen receptor chimera.Biochim Biophys Acta2003
12226757Cell transformation by v-Jun deactivates ERK MAP kinase signalling.Oncogene2002
10713176v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.Mol Cell Biol2000
10996792Transient deactivation of ERK signalling is sufficient for stable entry into G0 in primary avian fibroblasts.Curr Biol2000
11127822v-Jun sensitizes cells to apoptosis by a mechanism involving mitochondrial cytochrome C release.Oncogene2000
9837920Analysis of the interaction between c-Jun and c-Jun N-terminal kinase in vivo.J Biol Chem1998
9427647An oncogenic mutation uncouples the v-Jun oncoprotein from positive regulation by the SAPK/JNK pathway in vivo.Curr Biol1998
9101083Transformation by v-Jun prevents cell cycle exit and promotes apoptosis in the absence of serum growth factors.Cell Growth Differ1997
8262050Transcription activation by Myc and Max: flanking sequences target activation to a subset of CACGTG motifs in vivo.EMBO J1993
8510929Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.Oncogene1993
  • 1 - 47 of 47

Recommended Authors

The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Moffitt Cancer Center
Career Start Year 2006
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
University of Georgia
Career Start Year 1994
Number of shared co-authors 1
Institut Curie
Career Start Year 1993
Number of shared co-authors 1
Case Western Reserve University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 0
Department of Pediatrics Stanford University Stanford California USA.
Career Start Year 1993
Number of shared co-authors 1
Lilly Research Laboratories
Career Start Year 1992
Number of shared co-authors 0
University of Colorado Anschutz Medical Campus
Career Start Year 1991
Number of shared co-authors 0
University of Toronto
Career Start Year 1990
Number of shared co-authors 1
University of Toronto
Career Start Year 1988
Number of shared co-authors 5
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 0
The Institute of Cancer Research
Career Start Year 1988
Number of shared co-authors 1
Rutgers New Jersey Medical School
Career Start Year 1987
Number of shared co-authors 4
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 1
Oregon Health and Science University
Career Start Year 1987
Number of shared co-authors 1
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 0
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 3
Laboratorio Nazionale-Consorzio Interuniversitario per le Biotecnologie
Career Start Year 1987
Number of shared co-authors 2
Moores Cancer Center, University of California San Diego
Career Start Year 1984
Number of shared co-authors 2
Institute for Research in Immunology and Cancer
Career Start Year 1982
Number of shared co-authors 0
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 6
Hollings Cancer Center, Medical University of South Carolina
Career Start Year 1979
Number of shared co-authors 0
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 1
Johns Hopkins University School of Medicine
Career Start Year 1978
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 1977
Number of shared co-authors 1
Frederick National Laboratory for Cancer Research
Career Start Year 1975
Number of shared co-authors 1
University of Rochester Medical Center, Wilmot Cancer Institute
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 7
College of Medicine, University of Glasgow
Co-authored papers 5
The Beatson Institute
Co-authored papers 4
Beatson Institute for Cancer Research and the University of Glasgow
Co-authored papers 4
Penn Epigenetics Institute, Perelman School of Medicine
Co-authored papers 3
Beatson Institute for Cancer Research and University of Glasgow
Co-authored papers 3
Oncode Institute
Co-authored papers 2
Queen's University Belfast
Co-authored papers 2
Beatson Cancer Research Institute, University of Glasgow
Co-authored papers 2
Queens University Belfast Belfast
Co-authored papers 2
Ludwig Institute for Cancer Research, University of Oxford
Co-authored papers 2
GE Global Research Center
Co-authored papers 2
Harvard University
Co-authored papers 1
Princess Maxima Center for Pediatric Oncology
Co-authored papers 1
University of Michigan School of Medicine ann arbor
Co-authored papers 1
Princess Maxima Center for Pediatric Oncology
Co-authored papers 1
University of British Columbia
Co-authored papers 1
University of North Dakota
Co-authored papers 1
Institute of Genetics and Molecular Medicine, University of Edinburgh
Co-authored papers 1
Karolinska Institutet
Co-authored papers 1
Wihuri Research Institute
Co-authored papers 1
University of Pennsylvania
Co-authored papers 1
University of British Columbia
Co-authored papers 1
Co-authored papers 1
Institute of Biochemistry II, Goethe University Frankfurt
Co-authored papers 1
MRC Institute of Genetics and Cancer, University of Edinburgh
Co-authored papers 1
Oncology R&D
Co-authored papers 1
Institute of Genetics and Cancer, University of Edinburgh
Co-authored papers 1
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Co-authored papers 1
Islamic University of Science and Technology
Co-authored papers 1